Patent Application
20230189790
The present invention relates to a storage liquid for preserving cells, tissues, organoids, organs, etc. in a non-frozen state. In particular, it relates to a refrigerated storage liquid for storage at a temperature lower than room temperature, for example, 2 to 15° C., 2 to 8° C. or 2 to 6° C. Further, in particular, for storing, by suspending or immersing, pluripotent cells such as human iPS cells and other stem cells, derivatives such as organoids obtained from them, early embryos, etc.
Convenient, efficient and stable storage and supply of stem cells such as iPS and ES cells is an important technology that is indispensable in the fields of basic research and clinical application research or drug discovery research, in regenerative medicine. Cryopreservation of human iPS cells and ES cells has many problems such as: low survival rate after storage when the slow-freezing cryopreservation method is used; cytotoxicity of DMSO, which is a cryoprotective agent used for cryopreservation; and differentiation inducing capability. Non-freezing low-temperature storage of cells is a very attractive technique as a short-term (for example, 1 day to 2 weeks) to medium-term (for example, half a month to 3 months) preservation method, and in same time would be very advantageous in preservation of differentiation-induced cells and the preservation of organoids when the industrialization of regenerative medicine technology and its application to drug discovery are considered. However, it is difficult to cryopreserve pluripotent stem cells including human iPS cells using UW solution (UW_sln; BELZER UW® COLD STORAGE LIQUID), which is widely used as a cryopreservation liquid for organs. Therefore, it is essential to develop a new refrigerated storage technology.
UW solution is widely used for refrigerated storage of organs used for transplantation such as liver and kidney, and it is practically a de facto standard or gold standard for such. The UW solution was developed in the 1980s and has a rather simple composition having an intracellular-type salt composition of low Na ion content and high K ion content, and containing lactobionat, raffinose, glutathione, hydroxyethyl starch.
The following patent documents are known:
The following non-patent documents are known:
However, when to store cells or tissues in a non-freezing refrigerated state, UW solution cannot sufficiently suppress low-temperature storage stress. To solve this problem, the inventors of the present invention have hypothesized that it was important to adopt an intermediate between: the intracellular type compositions represented by the UW solution; and extracellular type compositions having high Na ion content and low K ion content that are common in generally used culture media. In addition, we have conceived and idea that the addition of macromolecules such as proteins is important on contrary to organ preservation. Thus, the inventors have investigated storage liquids that have compositions at an intermediate between the UW solution and the cell culture media.
There are few reports on the low-temperature storage medium for cells. There are only a few reports of storage by using recently developed HTS FRS (Hypothermosol® FRS; BioLife Solutions). It has been reported that this HTS FRS can store human skin fibroblasts and smooth muscle cells at the low temperature for 3 to 5 days, but there is no report on the non-freezing refrigerated storage of pluripotent cells such as human iPS cells.
While trying a wide variety of combinations, the inventors of the present invention have adopted mixing, at a ratio of about 1/1 to ½: MEM-alpha (Minimum Essential Medium Eagle (MEM) Alpha Modification) or StemFit® AK02N (Ajinomoto Co., Inc.); with the above UW solution or a “ES cells culture liquid”, which is a modification based on DMEM: F12 medium as described later and hereinafter occasionally referred to as “ESC medium”. The MEM-alpha is a modification based on MEM medium and contains non-essential amino acids, sodium pyruvate, lipoic acid, biotin and vitamin B12.
The MEM (Eagle’s minimal essential medium) medium contains the following components (1) to (4).
On the other hand, the UW solution is a Ca2+-free solution having an intracellular fluid composition, and contains: lactobionic acid and hydroxy-ethyl starch (HES) for adjusting osmotic pressure and suppressing cell expansion; adenosine as anti-inflammatory and vascular relaxation agent and as a precursor of ATP; glutathione and alloprinol for antioxidants; and a phosphate buffer as a buffer component.
StemFit® AK02N is a feederless culture medium for human iPS cells, consisting of 400 mL of solution “A”, 100 mL of solution “B”, and 2 mL of solution “C”, and is used by mixing immediately before use. At a time of mixing the solutions “A” to “C”, the above-mentioned UW solution or “ES cells culture liquid” was also admixed with them. The solution “C” is a physiological buffer solution in which a basic fibroblast growth factor (bFGF) is dissolved.
When compared with MEM-alpha, StemFit® AK02N can be said to have the same salt composition, the essential amino acid composition is almost the same, and the non-essential amino acid composition is largely the same. As suggested by the experimental results described later, MEM-alpha and StemFit® AK02N could be used in almost the same manner in the refrigerating storage liquid of the present invention. Common features among these two media are considered to be important for the non-freezing refrigerated storage liquid for stem cells according to present invention, as suggested by experimental data presented later. The common features here are compositions of salts and essential amino acids and major part of composition of the non-essential amino acids. On the other hand, the main difference between MEM-alpha and StemFit® AK02N is that both proteins and growth factors are contained only in StemFit® AK02N. It is presumed that these components are not essential and do not contribute much to the refrigerating storage liquid of the present invention. While StemFit® AK02N is a culture medium for iPS cells, MEM-alpha cannot culture iPS cells even if bFGF, which is a typical growth factor, is added. Similarly, the ES cell culture medium (“ESC medium”) cannot culture iPS cells without feeder cells.
The DMEM: F12 medium, which is the base of the ES cell culture medium (“ESC medium”), is a mixture of MEM (Eagle’s minimal essential medium) medium and Ham’s F12 medium in a volume ratio of 1/1. The Ham’s F12 medium is a serum-free basal media containing putrescine, hypoxanthine and thymidine.
The non-freezing refrigerated storage liquid according to an aspect of the present invention has features A1 to A6 or A1 to A9 at below.
A1. Content of potassium ion species is 20 to 90 mmoL/L or 30 to 80 mmoL/L, and the content of sodium ion species is 20 to 90 mmoL/L or 30 to 80 mmoL/L.
A2. Ion-based molar ratio (Na+ / K+ ratio) of sodium ion species to potassium ion species is 0.5 to 1.5, 0.5 to 1.3, or 0.6 to 1.2.
A3. Trolox or its analog is contained at concentrations of 0.5-10 mM, 1-8 mM or 2-7 mM.
A4. Adenine or a salt or derivative thereof is contained at a concentration of 0.1 to 4.2 mM, 0.1 to 6 mM, 1 to 6 mM, 2 to 5 mM or 3 to 5 mM.
A5. All or all but one, two or three essential amino acids are contained, and the total content of essential amino acids is preferably 50 to 250 mg/L, particularly 50 to 200 mg/L or 80 to 150 mg/L.
A6. Total content of non-essential amino acids is preferably 100 to 500 mg/L, especially 50 to 200 mg/L or 80-150 mg/L.
A7. Content of magnesium ion species (particularly in magnesium sulfate) is 2 to 8 mmoL/L, 2 to 5 mmoL/L or 2-4 mmoL/L, and the calcium content is 0.2 to 1.5 mmoL/L, 0.2 to 1 mmoL/L or 0.3 to 0.8 mmoL/L.
A8. Glucose or other low-molecular-weight polysaccharides (particularly, disaccharides such as maltose, and monosaccharides such as fructose) is contained at a concentration of 0.5 to 10 mmoL/L.
A9. Vitamins at below are contained whereas one, two or three among the below can be omitted.
Folic acid, nicotinamide, riboflavin, B12, choline, inositol, pantothenic acid, pyridoxal phosphate, and thiamine.
The non-freezing refrigerated storage liquid according to an aspect of the present invention is a physiological solution, pH of which is set in a range of 7 to 7.5, and includes:
This non-freezing refrigerated storage liquid preferably further includes:
In occasions of non-freezing refrigerated storage of pluripotent cells such as human iPS cells, it is able to maintain a high viability maintenance effect and proliferative ability after recultivation.
The non-freezing refrigerated storage liquid according to a preferred embodiment of the present invention is a physiological buffer solution, pH of which is set to 7 to 7.5, includes (i) to (vi) at below.
(i) Lactobionic acid or a salt thereof (lactobionate) in terms of lactone 20-100 mmoL/L, 30-100 mmoL/L, 30-80 mmoL/L or 30-60 mmoL/L, or 10-50 g/L, 10-40 g/L, 15-35 g/L or 20-30 g/L.
(Ii) Raffinose hydrate 10-40 mmoL/L, 10-30 mmoL/L or 10-20 mmoL/L, or 5-20 g/L or 8-15 g/L.
(iii) Allopurinol 0.3 to 2 mmoL/L, 0.3 to 1 mmoL/L or 0.4 to 0.8 mmoL/L, or 0.03 to 0.15 g/L, 0.05 to 0.1 g/L or 0.06 to 0.08 g/L.
(iv) Glutathione (total glutathione) 1-3 mmoL/L or 1.5-2.5 mmoL/L, or 0.3-1 g/L, 0.4-0.9 g/L or 0.4-0.8 g/L.
(v) Adenosine 2-10 mmoL/L, 2-8 mmoL/L or 2-5 mmoL/L, or 0.5-1.5 g/L or 0.5-1.3 g/L.
(vi) Lipoic acid 0.05 to 1 µmoL/L, 0.1 to 0.5 µmoL/L or 0.2 to 0.4 µmoL/L, or 0.03 to 0.2 mg/L or 0.05 to 0.1 mg/L.
(vii) Sodium pyruvate 0.1 to 1 mmoL/L, 0.1 to 0.7 mmoL/L or 0.2 to 0.5 mmoL/L, or 10 to 100 mg/L or 20 to 50 mg/L.
(viii) Glucose 0.5 to 10 mmoL/L, 1 to 5 mmoL/L or 1 to 3 mmoL/L, or 100 to 1000 mg/L or 200 to 500 mg/L.
(ix) antioxidant vitamins or their water-soluble analogs/derivatives, in the following.
Each in the following take a form of salt. In some cases, ix-1 may be omitted.
ix-1. Ascorbic acid 0.03 to 0.3 mmoL/L, 0.05 to 0.2 mmoL/L or 0.05 to 0.15 mmoL/L, or 5 to 20 mg/L or 10 to 15 mg/L.
ix-2. Vitamin E, trolox or other water-soluble vitamin E analog/derivatives 0.5-10 mM, 1-8 mM or 2-7 mM.
(x) Adenine or its salt or derivative 0.1-6 mM, 0.1-5 mM, 0.1-4.5 mM, 0.1-4.2 mM or 2-5 mM, and in some cases, 0.1-0.3 mM or 0.05-0.2 mM.
(xi) Other vitamins not mentioned above, or water-soluble analog derivatives thereof
Each in the following may take a form of salt. And, out of ten compounds in the following, one to five compounds, one to four compounds, or one to three compounds may be omitted.
xi-1. Biotin 0.03 to 0.25 µmoL/L, 0.05 to 0.2 µmoL/L or 0.1 to 0.15 µmoL/L, or 0.01 to 0.1 mg/L or 0.02 to 0.05 mg/L.
xi-2. Vitamin B12 0.03 to 3 µmoL/L, 0.05 to 2 µmoL/L or 0.1 to 0.5 µmoL/L, or 0.1 to 0.8 mg/L or 0.2 to 0.6 mg/L.
xi-3. Folic acid 0.2-2 µmoL/L, 0.3-1 µmoL/L or 0.5-0.9 µmoL/L, or 0.1-1 mg/L or 0.2-0.5 mg/L.
xi-4. Niacinamide 0.5-8 µmoL/L, 1-6 µmoL/L or 1-4 µmoL/L, or 0.03-0.2 mg/L or 0.05-0.1 mg/L.
xi-5. Riboflavin 0.03 to 0.3 µmoL/L, 0.04 to 0.2 µmoL/L or 0.05 to 0.15 µmoL/L, or 0.03 to 0.2 mg/L or 0.05 to 0.1 mg/L.
xi-6. Choline 0.05 to 1 µmoL/L, 0.1 to 0.5 µmoL/L or 0.1 to 0.4 µmoL/L, or 0.1 to 1 mg/L or 0.2 to 0.5 mg/L.
xi-7. Inositol 1-10 µmoL/L, 1-8 µmoL/L or 2-6 µmoL/L, or 0.03-0.2 mg/L or 0.05-0.1 mg/L.
xi-8. Pantothenic acid 0.02 to 0.2 µmoL/L, 0.03 to 0.1 µmoL/L or 0.04 to 0.08 µmoL/L, or 0.1 to 1 mg/L or 0.2 to 0.5 mg/L.
xi-9. Pyridoxal 0.5 to 3 µmo L/L, 0.1 to 2 µmo L/L or 1 to 2 µmo L/L, or 0.1 to 1 mg/L or 0.2 to 0.5 mg/L.
xi-10. Thiamine 0.3 to 3 µmoL/L, 0.4 to 2 µmoL/L or 0.5 to 1.5 µmoL/L, or 0.1 to 1 mg/L or 0.2 to 0.5 mg/L.
(xii) Essential amino acids 50-200 mg/L or 80-150 mg/L in total.
Amount of each component may be in a range of A/3 to 3A or of A/2 to 2A, where A is the value obtained by dividing by 3, the content shown in Table 2 or the value in “HTM-alpha” in Examples mentioned later. That is, amount of each component may be set in a range of ⅓ to 3 times, or in a range of ½ to 2 times, of the value in “HTM-alpha”. The same applies to the dictated non-essential amino acids and the vitamins mentioned above.
(xiii) Non-essential amino acids in the following, 100-500 mg/L or 150-400 mg/L in toral.
Each in the following may take a form of salt. And, out of ten compounds in the following, one to five compounds, one to four compounds, or one to three compounds may be omitted.
(xiv) Potassium ion species 20-90 mmoL/L, 30-80 mmoL/L, 40-80 mmoL/L or 50-70 mmoL/L. Namely, 20 mmoL/L or more, 30 mmoL/L or more, 40 mmoL/L or more, or 50 mmoL/L or more, and less than 90 mmoL/L, less than 80 mmoL/L, or less than 70 mmoL/L.
(xv) Sodium ion species 20-90 mmoL/L, 30-80 mmoL/L, 40-80 mmoL/L or 50-70 mmoL/L. Namely, 20 mmoL/L or more, 30 mmoL/L or more, 40 mmoL/L or more, or 50 mmoL/L or more, and less than 90 mmoL/L, less than 80 mmoL/L, or less than 70 mmoL/L.
This non-freezing refrigerated storage liquid preferably contains at least one of the following (xvi) to (xviii). Particularly preferably, the following (xvi) to (xvii) and the following (xviii) are included.
(xvi) Hydroxyethyl starch 10-80 g/L, 20-50 g/L or 20-40 g/L.
(xvii) Polyvinyl alcohol 3-100 g/L, 5-80 g/L, 5-50 g/L, 5-30 g/L, 5-25 g/L, or 5-20 g/L.
(xviii) Mannitol 20-100 mmoL/L, 30-90 mmoL/L or 20-90 mmoL/L.
This non-freezing refrigerated storage liquid preferably contains at least one of the following (xix) and (xx).
(xix) Ribonucleoside 2-4 types Total 4-40 mg/L, 5-30 mg/L or 10-15 mg/L.
(xx) Deoxyribonucleosides 2-4 types Total 4-40 mg/L, 5-30 mg/L or 10-15 mg/L.
This non-freezing refrigerated storage liquid preferably contains the following (xxi) to (xxiii).
(xxi) Potassium dihydrogen phosphate or sodium dihydrogen phosphate 10-30 mmoL/L, 10-25 mmoL/L, or 15-25 mmoL/L.
(xxii) Magnesium ion species (especially as magnesium sulfate) 2 to 8 mmoL/L, 2 to 5 mmoL/L or 2 to 4 mmoL/L.
(xxiii) Calcium ion species (especially as magnesium chloride) 0.2 to 1.5 mmoL/L, 0.2 to 1 mmoL/L or 0.3 to 0.8 mmoL/L.
Further, according to a preferred embodiment of the present invention, in term of molar ratio (ratio of Na/K ions), amount of the sodium ion species is, for example, 0.7 to 1.3 times, 0.8 to 1.2 times, or 0.9 to 1.1 times that of the potassium ion species. According to another preferred embodiment, amount of the sodium ion species may be, for example, 0.5 to 1.5 times, 0.5 to 1.3 times, or 0.6 to 1.2 times of the potassium ion species, in the term of molar ratio.
As described above, the non-freezing refrigerated storage liquid according to the preferred embodiment of the present invention contains trolox or other water-soluble vitamin analogs in an amount of 0.1 mM or more, 0.3 mM or more, 0.5 mM or more, 1 mM or more, 2 mM or more, 3 mM, 4 mM or more, or 5 mM or more; and 10 mM or less, 8 mM or less, or 6 mM or less.
As described above, the non-freezing refrigerated storage liquid according to the preferred embodiment of the present invention contains, in particular, adenine or a salt thereof at 0.1 mM or more, 0.3 mM or more, 0.5 mM or more, 1 mM or more, 2 mM or more, 3 mM or more; and 8 mM or less, 6 mM or less, 5 mM or less or 4 mM or less; and, for example, 0.1 to 4.2 mM or 1 to 4.2 mM. In particular, it is considered that the addition of adenine has a remarkable effect in preserving embryos and organoids in which cells are adhered to each other to form a three-dimensional mass. In addition, in preserving embryos and organoids, effects were observed even at relatively low concentrations, for example, 0.01 to 0.2 mM (10 to 200 µM) or 0.05 to 0.3 mM (5 to 300 µM) (
The non-freezing refrigerated storage liquid according to the preferred embodiment of the present invention further includes L-alanyl-L-glutamine, or other dipeptide substitute, or a salt thereof, at a concentration of 1 to 6 mM, 2 to 5 mM, or 3 to 5 mM.
The refrigerated storage liquid according to a preferred embodiment of the present invention is obtainable by mixing a UW solution having a composition shown in Table 1 with the MEM alpha medium having a composition shown in Table 2, so that amount of the UW solution is 1 to 3 times, preferably 1.5 to 2.5 times, more preferably 1.8 to 2.2 times of amount of the MEM alpha medium, in a volume ratio. The compositions of Tables 1 and 2 and the content of each component obtained from the above mixing ratio may be increased or decreased within a range of ± 50%, ± 40%, ± 30%, or ± 20% if necessary or appropriate. In addition, out of the components listed in Table 2, some components are omittable. Particularly omittable are: some of the non-essential amino acids (for example, 1 to 5 amino acids); some of the nucleosides (for example, 1 to 5 nucleosides); some vitamins (for example, 1 to 5 vitamins); some inorganic salts (for example, 1 to 3 salts), and phenol red.
A non-freezing refrigerated storage method according to a preferred embodiment of the present invention includes: dispersing pluripotent cells in any of the above refrigerated storage liquids so that the cells are dispersed in a single cell state in a range of 1×103 cells/mL to 1 × 10 cells/mL, or 1×104 cells/mL to 1×108 cells/mL; and storing in non-freezing refrigerated state for 1 to 10 days or 1 to 7 days, for example.
A non-freezing refrigerated storage method according to a preferred embodiment of the present invention includes: seeding pluripotent cells into a culture container containing any of the above refrigerated storage liquids in a range of 1×103 cells/cm2 to 1×109 cells/cm2 or 1×104 cells/cm2 to 1×108 cells/cm2; culturing for 2 to 6 days in such state; and then storing in non-freezing refrigerated state for 1 to 10 days or 1 to 7 days, for example.
According to a preferred embodiment of the present invention, the pluripotent cells or stem cells to be stored in a non-freezing refrigerated state are pluripotent cells such as ES cells and induced pluripotent stem cells such as iPS cells, or hematopoietic stem cells, nerve stem cells, and liver stem cells, skin stem cells, reproductive stem cells, etc. In addition, the pluripotent cells to be stored in a non-freezing refrigerated state may be of human origin or originated from mammals such as primates, mice and guinea pigs.
Further, according to another embodiment, target of non-freezing refrigerated storage may be human or animal embryos, particularly embryos of domestic animals such as cows, horses, pigs and goats.
A healthy human-derived human iPS cell line (253G1) obtained from the Center for iPS Cell Research and Application, Kyoto University was maintained and cultured under feeder-free conditions. For this culture, StemFit (registered trademark) AK02N (Ajinomoto), which is a commercially available medium for clinical research for human ES/iPS cells was used. When the cells reached 70-80% confluence on the 7th day after the start of the culture, the cells were enzymatically stripped off from a container by using 0.5X TrypLE® Select, and then dispersed and washed. Subsequently, the cells were suspended in a new StemFit® AK02N medium containing 10 µM Y27362 (Fujifilm Wako Pure Chemical Industries, Ltd.) as a ROCK inhibitor, and added with iMatrix-511 (MATRIXOME, Inc.) as a further cell culture substrate at 0.1 µg/cm2. Then, the cells were seeded at a concentration of 1.3E3/cm2 (1.3 ×103/cm2). The day after the seeding, the medium was replaced with StemFit® AK02N medium containing no Y27362, then the medium was replaced every 3 days and subcultured or tested on day 7.
For the experiment using the following HTM-alpha as the non-freezing refrigerated storage medium (
On the other hand, in order to try non-freezing refrigerated storage of mouse embryos (
In addition, in present application, unless otherwise specified, culturing was carried out in a 37° C. incubator (5% CO2).
The following 3 types of refrigerated storage liquids were prepared. For convenience, they will be referred to as HTM1, HTM2, and HTM-alpha, respectively.
Any of the following three types of refrigerated storage liquids was used as the refrigerated storage liquid of the comparative example.
Human ES cell culture medium (“ESC medium”) is obtainable by adding components listed below into DMEM-F12 (Invitrogen 21331-020). At below, “%” and “mM” below indicate the weight ratio or molar concentration with respect to the finally obtained human ES cell culture medium.
The composition of the UW solution (BELZER UW (registered trademark) COLD STORAGE LIQUID) is as shown in the table below according to Non-Patent Document 1 above.
Specifically, the MEM alpha medium (12571--MEM alpha, nucleosides, Thermo Fisher Scientific) used in “HTM-alpha” has the following composition (https://www.thermofisher.com/jp). /en/home/technical-resources/media-formulation.94.html).
GlutaMAX (registered trademark, GIBCO) added to “HTM-alpha” is a 200 mM solution (“GlutaMAX”) in which L-alanyl-L-glutamine, as a dipeptide substitute for L-glutamine, is dissolved in physiological saline (0.85 N NaCl). It is marketed as “GlutaMAX™ I (100 ×)”. This was added into “HTM-alpha” so as to be diluted by 1/20 to become 10 mM (5 ×) when using.
With regard to the UW solution, HTM1 to HTM2 and HTM-alpha in the above, and the commonly used culture solution Earls BSS (EBSS -Earle’s Balanced Salt Solution, ThermoFisher scientific); sodium ion concentration, potassium ion concentration, and molar ratios between these two are listed in Table 3. It should be noted that StemFit (registered trademark) AK02N and MEM-alpha also have the same ion concentration as Earls BSS. In view of experimental results described later, it is considered that the molar ratio of Na+ /K+ should be around 1 or a little smaller.
As mentioned above, proteins, peptides, and growth factors are contained in StemFit® AK02N, but not in MEM-alpha. Therefore, proteins, peptides, and growth factors are contained in HTM1, but not in HTM-alpha.
The human iPS cells obtained in “1.” above are added into the refrigerated storage liquids HTM1 and HTM2 in “2.” above to be suspended at 1E6 cells/mL (number of floating cells 1x106 cells/mL) in a cell state. Then, the suspensions were placed into a plastic tube and allowed to stand at 4° C. for storage. The survival rate was determined by counting the number of living cells after staining with trypan blue.
The results of survival rate measurement over time are shown in
The statistical processing in the examples of the present application was performed as follows. The survival rate maintenance curves in
As shown in
Since the StemFit (registered trademark) medium used for HTM1 is free of animal-derived components (Xenofree), subsequent experiments were examined using HTM1. When the “ESC medium” was used as it was for non-freezing refrigerated storage, the survival maintenance effect was significantly lower than that of the UW solution. While “ESC medium” was used in experiments below, results are shown only in the graph and explanation will be omitted.
The cell proliferation ability after non-freezing refrigerated storage was verified as follows. First, the human iPS cells obtained in the above “1.” were placed into the refrigerated storage liquid HTM1 of the above “2.” and stored in the non-freezing refrigerated state for 6 days as in the above “3.”. The cells were then suspended in StemFit® AK02N medium containing 10 µM Y27362, into which iMatrix-511 was added by 0.1 µg/cm2. and seeded at a concentration of 1.3E3/cm2. On 5th day of culturing, the cells were stained with fixed alkaline phosphatase, and then the number of colonies formed to a certain size or larger was measured using a colony counter. The number of colonies when cultured for 5 days without being subjected to the refrigerated storage was similarly measured and used as a control. Then, the number of colonies obtained by culturing for 5 days after the refrigerated storage was divided by the number of colonies in this control to obtain colony forming ability (Relative colony efficiency).
As shown in
The human iPS cells obtained in the above “1.” are placed in the refrigerated storage liquid HTM1 of the above “2.” and stored as in the above “3.” for 3 days; and the cell death occurring immediately after this is classified by using Annexin V/EthD-III. That is, in order to distinguish apoptotic cells and necrotic cells from the others, firstly, the cells were stained according to the protocol by using the Apoptotic/Necrotic Cells Detection Kit (TAKARA). Then, Annexin V-FITC positive cells (apoptosis), ethidium homodimer III positive cells (necrosis), and Hoechst33342 (Dojin) signal (whole cells) were observed and measured under a fluorescence microscope.
The results are shown in bar graphs of
In the refrigerated storage, it is important to maintain viability during the refrigerated storage period, but it is more important to suppress cell death that occurs during recultivation after the storage. In order to elucidate the cause of cell death that occurs after the start of low-temperature storage and recultivation, intracellular reactive oxygen species (ROS) were measured by using Aminophenyl Fluorescein (APF). Specifically, the measurement was performed as follows. Firstly, Aminophenyl Fluorescein (APF) (five ridger) was added to the medium after the refrigerated storage for 3 days in the same manner as in “5.” above so as to achieve final concentration of 5 µM. And, addition here was made throughout a period of 30 minutes in an incubator of 5% CO2, 5% O2 and 37° C. Subsequently, the culture medium was replaced, and in same time, 10 µM of Hoechst33342 (Dojin) was added to perform counter-staining, and then image of the counter-staining was observed with a fluorescence microscope and photographed. The fluorescence signal of each cell was quantified by using the image analysis software ImageJ.
This result is shown in
In the same manner as in “5.” above, the activity of intracellular caspase 3/7, which is an index of apoptosis, was measured for cells that had been stored for 3 days in the refrigerated state as in the above. First, Staining was performed according to the protocol using CellEvent ™ Caspase-3/7 Green Detection Reagent (Thermo Fisher). Then, the fluorescence signal of each cell was quantified using the image analysis software ImageJ.
This result is shown in
Antioxidants or radical scavengers were added to HTM1 at various concentrations and subjected to the non-freezing refrigerated storage test as described in “3.” above. The added antioxidants or radical scavengers are shown in
The effect of trolox, which had the highest viability-maintaining effect, was further investigated by varying the addition concentration from 0.1 mM to 0.5 mM.
Next, in order to verify the proliferative ability after refrigerated storage and recultivation, cells having been stored in the refrigerated state for 6 days were seeded in the same manner as in “4.” above, and the colony forming ability on the 5th day of culturing was compared. As shown in
The HTM-alpha (UW solution + MEM-alpha, 2: 1) described in “2.” above, which has not been added with trolox and GlutaMAX (registered trademark, GIBCO), is used in
Human iPS cells obtained in the same manner as in “1.” above were used. However, at the final stage of culturing, the cells were seeded at a slightly lower concentration (1.0E3/cm2) than the maintenance culture of “1.” above, and the day after this seeding, culture medium was replaced by StemFit® AK02N medium containing no Y27362. Then, the medium was removed 4 days after the seeding.
Subsequently, the medium was replaced with HTM1 which is for the non-freezing refrigerated storage, and the medium with the cells was left to stand for 3 or 6 days under 4° C. In other words, in a state the cells were aggregated and adhered to each other, the cells were stored in non-freezing refrigerated condition for 3 days or 6 days. Trolox was added to HTM1, which is the medium for refrigerated storage. In addition, adenine hydrochloride (Tokyo Kasei) was added to such media so as to become 0 mM, 1.4 mM and 4.1 mM, respectively. A UW solution (BELZER UW (registered trademark) COLD STORAGE LIQUID) was also used as the refrigerated storage medium of the comparative example.
The cells after the non-freezing refrigerated storage were lightly washed with culture medium after the refrigerated storage medium were removed. Then, StemFit® AK02N medium was added and culturing was made for 4 days. At the end of this culturing, cells were enzymatically detached (by using 0.5X TrypLE® Select), and dispersed so that number of viable cells are counted. Then, it was compared with the number of cells at the start of refrigerated storage. In addition, after taking a phase difference image at the end and start of the culturing, image processing was performed with ImageJ to extract and binarize the colony area, and the colony area was measured to evaluate the proliferative ability.
The above experiment was aimed at developing a refrigerated storage method in a state iPS cells were adhered, and proliferative ability (colony forming ability) subsequent to culturing for 4 days after the non-freezing refrigerated storage for 3 or 6 days. The results of the experiment are shown in
In addition, the bar graph in
As shown in the upper left part of each of
On the other hand, as shown in the lower left and lower right parts of
By using the HTM-alpha (UW solution + MEM-alpha, 2: 1) described in the above “2.”, the refrigerated storage in the adhesive state was evaluated by the same operation as in the above “10.”. However, the evaluation was made subsequent to recultivation after the refrigerated storage for 7 days instead of 6 days. Here, as described above, 5 mM Trolox and 5-fold concentration (x5; 10 mM) GlutaMAX® (registered trademark, GIBCO) were added to HTM-alpha. In addition, HTM1 and HTS FRS were compared by using them at the same time under the same conditions. As with HTM-alpha, 5 mM Trolox and 5-fold concentration (x5; 10 mM) GlutaMAX® (registered trademark, GIBCO) were added to HTM1.
This result is shown in the graph of
From this result, it is considered that fibroblast growth factor (FGF) contained in the C solution of StemFit (registered trademark) AK02N is unnecessary or does not contribute much. In addition, among the components contained in StemFit (registered trademark) AK02N, those not contained in HTM-alpha were considered to be not essential. In particular, since HTM-alpha is a protein-free medium, it was considered that protein is not essential or should be absent.
As described above, a blastocyst stage embryo 3.5 days after in vitro fertilization was immediately used as it was, and a refrigerated storage experiment was conducted. Specifically, for this blastocyst stage embryo, the medium was replaced with the HTM-alpha, HTM1, and HTS FRS as used in the above “11.” and the UW solution, in respective experiments. The obtained suspension was then placed in a plastic tube and was allowed to be kept at 4° C. for 3 days (72 hours). Both of HTM-alpha and HTM1 here are obtained by adding 5 mM Trolox and 5-fold concentration (x5; 10 mM) GlutaMAX (registered trademark) in the same manner as in “11.” above.
As shown in
Next, the effect of adding adenine hydrochloride (Tokyo Kasei) was investigated in the same manner as in
As shown in Table 1 above, since the UW solution contains 5.0% hydroxy ehyl starch (HES), HTM-alpha (UW solution + MEM-alpha, 2/1) described in “2.” contains 3.3% hydroxyethyl starch (HES). Here, the effect of adding polyvinyl alcohol (PVA) instead of hydroxyethyl starch (HES) was investigated. Here, the composition of the UW solution shown in Table 1 above, excluding hydroxyethyl starch (HES), was adopted. Thus, the other components are same with those in the HTM-alpha (UW solution + MEM-alpha, 2: 1) while polyvinyl alcohol (PVA) in the range of 0.25% to 2.5% (weight) were added in the storage liquids used here. The cell viability was evaluated in the same manner as in the case of
Next, in the same manner as in “13.” above, mannitol was added together with polyvinyl alcohol (PVA), and the synergistic effect was verified. That is, polyvinyl alcohol (PVA) was added in the range of 0.5% to 5% to HTM-alpha (UW solution + MEM-alpha, 2: 1) without hydroxyethyl starch (HES), and cell membrane impermeable. Mannitol, which is considered to have a sexual osmoregulatory effect, was added with 0, 30, 60, and 90 mM. In addition, the protective effect was examined by the same procedure as in the cases of
When the cell cryopreservation medium HTM1 of the present embodiment in which the UW solution and the commercially available clinical research medium StemFit® AK02N were mixed at a ratio of 2/1 was used, as shown in
In addition, it is considered that the addition of an antioxidant/radical scavenger to HTM1 made it possible to suppress the rapid increase in ROS concentration that occurs at the start of recultivation after the refrigerated storage. With the addition of Trolox 5 mM, as shown in 6A and 6B, the maintenance period of 80% survival rate could be 20 days or more, which was about 4 times that of HTM1 without Trolox addition. In addition, as shown in
On the other hand, when cryopreserved in the adhered state, it was clarified that the addition of Adenine in addition to the addition of trolox increased the subsequent growth rate, as shown in
On the other hand, when the cell cryopreservation medium “HTM-alpha” (UW solution + MEM-alpha, 2/1) of a particularly preferable embodiment obtained by mixing UW solution and MEM alpha was used; as shown in
Although the storage period of iPS cells is limited as compared to frozen storage, iPS cell storage can be stored in a state of culturing and adhered state; and differentiation-induced organoids that cannot be frozen can be stored and transported. Or, it is a technology with a very high range of applications, such as on-demand cell supply in drug discovery research. Therefore, this technology, which enables the preservation of human iPS cells, is extremely important.
In view of that the cell refrigerated storage medium “HTM-alpha” of the embodiment of the present application was effective in storing mouse embryos in the non-freezing refrigerated state, the cell refrigerated storage medium of the embodiment would also be or may effective for strong the embryonic or non-embryonic stem cells of humans and various animals and tissues in the non-freezing refrigerated state.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2019-203124 | Nov 2019 | JP | national |
This application is the U.S. National Phase of International Application No. PCT/JP2020/041313, filed on Nov. 5, 2020. This application claims priority to Japanese Patent Application No. 2019-203124, filed Nov. 8, 2019. The entire contents of those applications are incorporated by reference herein in their entireties.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2020/041313 | 11/5/2020 | WO |
